Department of Chemistry, University of Nevada, Reno, NV 89557-0216, USA.
Department of Chemistry, University of Nevada, Reno, NV 89557-0216, USA.
Bioorg Med Chem Lett. 2020 May 15;30(10):127115. doi: 10.1016/j.bmcl.2020.127115. Epub 2020 Mar 17.
Many current and potential drug targets are membrane-bound or secreted proteins that are expressed and transported via the Sec61 secretory pathway. They are targeted to translocon channels across the membrane of the endoplasmic reticulum (ER) by signal peptides (SPs), which are temporary structures on the N-termini of their nascent chains. During translation, such proteins enter the lumen and membrane of the ER by a process known as co-translational translocation. Small molecules have been found that interfere with this process, decreasing protein expression by recognizing the unique structures of the SPs of particular proteins. The SP may thus become a validated target for designing drugs for numerous disorders, including certain hereditary diseases.
许多当前和潜在的药物靶点是膜结合或分泌蛋白,它们通过 Sec61 分泌途径表达和运输。它们通过信号肽 (SP) 被靶向到内质网 (ER) 膜上的易位子通道,SP 是新生链 N 末端的临时结构。在翻译过程中,这些蛋白质通过共翻译易位过程进入 ER 的腔和膜。已经发现了一些小分子,可以通过识别特定蛋白质的 SP 的独特结构来干扰这个过程,从而减少蛋白质的表达。因此,SP 可能成为设计治疗许多疾病(包括某些遗传性疾病)药物的有效靶点。